


Accepted Manuscript

'Acute Flare-Ups' In Patients With, Or At High Risk Of, Knee Osteoarthritis: A Daily Diary Study With Case-Crossover Analysis

Dr Emma Parry, Dr Reuben Ogollah, Associate Professor, George Peat, Professor



PII: S1063-4584(19)30924-0

DOI: <https://doi.org/10.1016/j.joca.2019.04.003>

Reference: YJOCA 4439

To appear in: *Osteoarthritis and Cartilage*

Received Date: 19 November 2018

Revised Date: 1 April 2019

Accepted Date: 5 April 2019

Please cite this article as: Parry E, Ogollah R, Peat G, 'Acute Flare-Ups' In Patients With, Or At High Risk Of, Knee Osteoarthritis: A Daily Diary Study With Case-Crossover Analysis, *Osteoarthritis and Cartilage*, <https://doi.org/10.1016/j.joca.2019.04.003>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Title page**

2 'ACUTE FLARE-UPS' IN PATIENTS WITH, OR AT HIGH RISK OF, KNEE OSTEOARTHRITIS: A
3 DAILY DIARY STUDY WITH CASE-CROSSOVER ANALYSIS

4

5 Dr Emma Parry

6 *SPCR GP Progression Fellow, Arthritis Research UK Primary Care Centre, Research Institute for*

7 *Primary Care & Health Sciences, Keele University, UK. Email: e.parry@keele.ac.uk*

8 Dr Reuben Ogollah

9 *Arthritis Research UK Primary Care Centre, Research Institute for Primary Care & Health Sciences,*

10 *Keele University, UK; Associate Professor of Medical Statistics and Clinical Trials, Nottingham Clinical*

11 *Trials Unit, School of Medicine, University of Nottingham, D Floor, South Block, QMC, Nottingham,*

12 *NG7 2UH, UK. Email: reuben.ogollah@nottingham.ac.uk*

13

14 Professor George Peat

15 *Professor of Clinical Epidemiology, Arthritis Research UK Primary Care Centre, Research Institute for*

16 *Primary Care & Health Sciences, Keele University, UK. Email: g.m.peat@keele.ac.uk.*

17

18

19 **ABSTRACT**

20 **Objective:** To determine the natural history of flare-ups in knee osteoarthritis and their
21 relation to physical exposures.

22
23 **Design:** Adults aged ≥ 45 years with a recent primary care consultation for knee
24 OA/arthritis completed a daily pen-and-paper diary for up to 3 months, including
25 questions on average knee pain intensity, pain descriptors, other symptoms, activity
26 interference, and selected physical exposures (prolonged kneeling, squatting, climbing
27 stairs, ladders, and moving/lifting heavy objects). Informed by a systematic review, flare-ups
28 were defined a priori. We calculated the rate of flare-ups in the sample, described their
29 nature and duration, and estimated their association with physical exposures in the prior 48
30 hours.

31
32 **Results:** 67 participants completed at least one month of diaries, 37 (55%) were female,
33 mean age 62 years (SD 10.6) with a mean body mass index of 24.6 kg/m^2 (SD 5.1). 30
34 participants experienced a total of 54 flare-ups (incidence density 1.09 flare-ups/person-
35 days). The median duration of flare-ups was 8 days (range: 2-30). During a flare-up
36 participants were more likely to report sharp, throbbing, stabbing, burning pain, swelling,
37 limping, stiffness, being woken by pain, taking more analgesia, and stopping usual activities.
38 Exposure to one or more physical exposure increased the risk of a flare-up in the
39 subsequent 48 hours (odds ratio 2.19 (95%CI: 1.22, 4.05)).

40
41 **Conclusions:** Our study with intensive longitudinal data collection suggests acute flare-ups
42 may be experienced by a substantial number of patients. These episodes often last a week

43 or longer, are disruptive, prompt changes in self-management, and may be triggered by
44 high-loading physical activities.

45

46 **Keywords:** Knee, osteoarthritis, flare-up

47

48 **Running headline:** Natural history of flare-ups in knee OA

49

ACCEPTED MANUSCRIPT

1 INTRODUCTION

2

3 Longitudinal studies following patients with symptomatic knee osteoarthritis over
4 several years suggest that non-progressive symptom trajectories are relatively common¹.
5 However, within these average long-term trajectories, it is well-recognised that patients can
6 experience substantial variability in the presence, nature, and severity of symptoms over
7 time, including episodes of increased pain that may be experienced as acute events^{2,3}.
8 These events, particularly when they have an unpredictable, sudden onset, can be
9 distressing for patients and can impact on quality of life, normal activities (including
10 productivity losses⁴) and health service use. Yet unlike other long-term conditions, there is
11 still considerable uncertainty around the nature, definitions, and terminology of these
12 phenomena in osteoarthritis. Classification criteria for flare-ups in knee OA have been
13 proposed but have not been widely adopted⁵. Achieving greater clarity and agreement on
14 these matters is an important goal for research and clinical communities⁶, toward which
15 observational research can contribute by gaining insight into the natural history of these
16 phenomena, possible triggers⁷, and other proximal and more distal determinants.

17

18 We sought to describe the natural history of 'flare-ups' in knee OA in a sample of
19 community-dwelling symptomatic adults, using an observational daily diary study. We chose
20 the term 'flare-up' over terms such as 'exacerbation' following workshops with patients and
21 members of the public on their preferred terminology and from more frequently used
22 terminology in the medical literature as found in a recent systematic review⁶

23 METHOD

24

25 Study design and sample

26

27 Adults aged 45 years and over registered at one of two General Practices in the
28 West Midlands, England and with a recorded consultation for knee osteoarthritis or knee
29 pain/arthritis in the previous 2 years were mailed a short questionnaire containing items
30 used to describe the sample, judge eligibility for the daily diary study, and provide baseline
31 values of 'what is normal for me' with respect to knee symptoms, activity, and analgesia
32 (adapted from Trappenburg et al⁸). A standard three-stage mailing procedure was used with
33 non-respondents sent a reminder postcard at two weeks and repeat questionnaire at four
34 weeks. Respondents were eligible for inclusion in the daily diary study if they reported knee
35 symptoms on at least one day in the previous 12 months, provided written informed
36 consent to further contact and indicated their willingness to complete daily diaries for up to
37 three months. Respondents were excluded if they self-reported a diagnosis of inflammatory
38 disease, previous bilateral total knee replacement (TKR) or TKR in the index knee (the worst
39 affected knee) or did not complete baseline knee symptom questions.

40

41 Data collection

42

43 All eligible, consenting questionnaire respondents were invited to complete three
44 consecutive one-month pen-and-paper diaries. The diaries contained nine items for each
45 day (see Supplementary Data 1) which participants were asked to fill out at the end of the
46 day. Average pain intensity in the previous 24 hours was assessed using a 0-10 numerical
47 rating scale (NRS)⁹. We included four single items on other symptoms shown by Marty et al⁵
48 to be associated with OA flare-ups: stiffness lasting >20 minutes, swelling, night pain and

49 limping. Participants were also asked about pain quality using a short list of descriptors
50 which included continuous pain descriptors (dull, aching, throbbing), intermittent pain
51 descriptors (sharp, stabbing), and neuropathic-type pain descriptors (burning, numbness,
52 pins and needles)^{3, 10}. Participants were asked if they had undertaken any of a selected list
53 of physical activities which have previously been linked to onset of knee OA¹¹. Participants
54 were also asked about any changes in usual medication (more than normal, less than
55 normal, the same) and whether symptoms had stopped them taking part in usual activities.

56

57 The study was approved by the North of Scotland Research Ethics Committee
58 (Reference: 13/NS/0049).

59

60 **Statistical analysis**

61

62 Scatterplots were used to visually inspect daily pain intensity scores for each participant. To
63 estimate within-person variability we calculated a Variability Index¹² for each participant
64 based on the average standard deviation of their daily pain intensity scores within half-
65 monthly periods. The periods ranged from 14-16 days due to the varying length of the
66 month over the three month study period. The standard deviation was chosen as it is the
67 most common measure of variability which averages the absolute deviation of each day's
68 pain intensity from the mean pain over the 14-16 days period thus capturing any pain
69 fluctuations. This method has also been used in a previous study investigating pain
70 variability of patients with fibromyalgia¹². The 14-16 day period was chosen based on the
71 number of available data points and to allow for reliable estimation of SD due to the
72 distribution assumptions. The possible values were positive, with zero indicating no

73 variability and a higher number indicating greater variability. Informed by a systematic
74 review of flare-up definitions in the medical literature⁶, and considering flare-up definitions
75 used in other conditions¹³ we defined a flare-up a priori as: an increase of at least two
76 points from baseline ('normal for me') in average pain intensity in the past 24 hours (0-10
77 NRS) which was sustained for at least two consecutive days. A flare-up was judged to be
78 resolved when pain intensity returned to baseline level for five consecutive days.

79

80 We then estimated the proportion of respondents experiencing at least one flare-up
81 during the period of observation, the incidence density with 95%CI of flare-ups for the
82 sample as a whole (expressed as the number of flare-ups per 100 person-days at risk, i.e.
83 denominator excluded days in flare-up and the five days needed for it to be judged
84 'resolved') using Poisson regression taking into account recurrent events, and the duration
85 of flare-ups (median, interquartile range (IQR)).

86

87 The time course of an 'average' flare-up was illustrated by plotting combined group-
88 mean daily pain intensity NRS scores across all first flare-ups, anchored to a common
89 timescale with zero representing the first day of flare-up and extending to 7 days prior and
90 30 days after the flare-up. To describe the nature of flare-ups and their impact on
91 individuals, descriptive statistics (means, SD or proportions) were used to summarise
92 symptoms, change in medication and whether pain had stopped usual activities across all
93 flare-up days and all non-flare-up days, among participants experiencing at least one flare-
94 up. We then used mixed-effect models to estimate the relative frequency (expressed as
95 odds ratios) and severity (expressed as regression coefficients) of symptoms on flare-up
96 versus non-flare-up days accounting for the clustered nature of the observations.

97

98 To determine whether exposure to selected physical activities was associated with
99 flare-up onset, we conducted a case-crossover analysis with each individual acting as their
100 own control¹⁴. Case windows for exposures were defined as the 48 hours prior to the first
101 day of a flare-up. For each case we selected up to four matched ambidirectional control
102 windows which were 48-hour periods on at-risk days which corresponded with the same
103 days of the week as the case window to remove confounding by variation in physical
104 exposures across days of the week (e.g. weekdays versus weekends). We calculated
105 unadjusted exposure odds ratios (OR) based on the conditional maximum likelihood
106 estimate with 95% mid-P exact confidence intervals using OpenEpi (www.OpenEpi.com).

107

108 Analyses were performed using Stata, Version 13 (StataCorp 2013).

109

110 RESULTS

111

112 Of the 220 out of 330 responders to the baseline questionnaire, 106 (48%) were eligible and
113 were invited to take part in the diary study, consented to further contact, and were mailed
114 the first diary. Reasons for non-eligibility included; inflammatory disease (41), TKR (27),
115 missing/blank Q (22), no recent knee pain (14), withdrew/died/moved (10). Of the 67 (63%)
116 participants who completed at least one monthly diary, 37 (55%) were female, mean age 62
117 years (SD 10.6) with a mean body mass index of 24.6 kg/m² (SD 5.1). Of a possible 5491
118 diary days, 4328 (79%) were fully completed, 1163 (21%) were partially completed, and 111
119 (2%) were missed completely. Comparing responders to non-responders ages were similar

120 (mean age 62.2 (SD 10.6) and 61.7 (SD 11.0) respectively) and there were slightly more
121 females amongst the non-responders (25 (64.1%) non-responders versus 37 (55.2%)).

122

123 The median Variability Index across the sample was 0.68 (IQR 0.41, 1.05), and this
124 was higher during non-flare-up days in participants classed as having experienced a flare-up
125 than in those participants who did not experience a flare-up ((median (IQR)): 0.83 (0.51,
126 1.13) vs 0.52 (0.27, 0.97).

127

128 Over the period of observation 30 participants (45%) were classed as having
129 experienced a total of 54 flare-ups (one flare-up (n=16), two flare-ups (n=6), three flare-ups
130 (n=6), four flare-ups (n=2)) giving an estimated incidence density of 1.12 (95%CI 0.80, 1.57)
131 flare-ups per 100 person-days. Illustrative examples of participants with contrasting
132 variability in daily pain scores are provided in Supplementary Data 2.

133

134 Those experiencing a flare-up were slightly more likely to be male (50% vs 40%;
135 proportion difference (95% CI): 10% (-14%, 33%)), have a higher BMI (mean (SD) 25.5 (5) vs
136 23.9 (6) kg/m²; mean difference (95% CI): 1.6(-0.9, 4.1)), and report previous injury (50% vs
137 42%; proportion difference (95% CI): 8% (-15%, 33%)), although none of these differences
138 were statistically significant given the relatively small numbers of participants in each group.

139

140 The median duration for a flare-up was 8 days (IQR 3, 23; range 2-30). The 'average'
141 time course shows the sudden onset and relatively quick reduction in pain intensity within
142 48 hours followed by a longish plateau (Figure 1). Flare-up days compared to non-flare-up
143 days were accompanied by a higher occurrence of knee stiffness (OR 10.9; 95% CI: 7.0,

144 17.1), limping (12.4; 7.4, 20.8), swelling (14.5; 8.3, 25.4), being woken by pain (7.0; 4.3,
145 11.2), use of most pain descriptors (but particularly 'throbbing', 'sharp', 'stabbing' pain, and
146 'numbness'), interference with usual activities (26.5; 3.7, 51.5) and taking more medication
147 than normal (23.9; 13.8, 41.4) (Table 1). The above features tended to be at their highest
148 levels during the first two days of a flare-up (data not shown).

149

150 For the case-crossover analysis using physical exposures there were 88 cases periods
151 in total and 328 control periods. The number of control periods per case ranged from 1-4
152 (median:2, mean: 2.43 (SD1.12)). Exposure to one or more of the selected physical
153 exposures (prolonged kneeling, lifting/moving heavy objects, climbing several flights of
154 stairs, prolonged squatting, climbing ladders) was associated with increased risk of acute
155 flare-up in the subsequent 48 hours (odds ratio 2.19; 95%CI: 1.22, 4.05) (Supplementary
156 Data 3). Exposure to each individual physical activity was positively associated with flare-up
157 onset but estimates lacked precision due to small numbers of discordant pairs.

158

159 **DISCUSSION**

160 Our study supports the notion that knee OA, for some people, is characterised by
161 intermittent acute or sudden increases in pain with an associated change in pain quality and
162 knee symptoms.

163

164 Pain intensity in our study was highly variable for some and stable for others.

165 Although not explored in this study, Schneider et al found a link between pain variability in
166 OA and depression¹⁵. Qualitative studies have highlighted the highly variable nature of pain
167 in OA² and when unpredictable can be associated with considerable distress³.

168

169 Predictability of pain is important for episode management and patient
170 understanding. Prior to flare-up onset we saw a marked step up in symptoms rather than a
171 gradual onset. This may be partly due to once daily measurement, however, we found that
172 certain activities reported in the 48-hour period prior to a flare-up were associated with
173 flare-up onset. Zobel et al identified that knee buckling and knee injury were triggers for
174 acute events⁷. Physical activity exposures have previously been associated with long term
175 incidence of osteoarthritis¹¹. The link we have found may give an insight into short term
176 events and their intrinsic part in how OA develops and progresses. It is possible that these
177 acute events lead to a cumulative insult on the knee joint that eventually leads to disability.

178

179 Identifying potential triggers are important in the management of flare-ups in terms
180 of activity avoidance and for earlier and preventative management strategies. Other
181 management strategies that may lead to early termination of a flare-up include recognising
182 the early changes in symptoms, for example knee stiffness, swelling, limping and night pain
183 which have previously been used as part of the criteria for flare-up identification⁵.

184 In response to flare-ups a third increased usual medication and a small number reported
185 stopping usual activities. Our study did not capture lesser but still problematic interference
186 with activities which may affect quality of life if sustained. We recognise that there may be
187 potential time-varying confounders that could not be controlled in the study, for example,
188 those causing psychosocial stress or a perceived improvement in symptoms, leading to a
189 reduction in medication and increase in activity.

190

191 Limitations of the study include the potential for inaccurate recall of average pain
192 scores over the 24-hour period and the extent to which participants may have
193 retrospectively filled in diary entries. We also acknowledge the bias that may be introduced
194 by missing data. Our case-crossover analysis was unable to explore individual physical
195 exposures due to small numbers and the use of ambidirectional control windows assumes
196 no strong effect of flare-ups on subsequent exposure levels.

197 In providing an operational definition of a flare-up we recognise the need for
198 continued empirical work. Sensitivity analyses in larger datasets could usefully explore
199 whether absolute or relative (to baseline) increases in pain are best for defining flare-ups as
200 well as the minimum duration of these.

201

202 **Conclusion**

203

204 Our study with intensive longitudinal data collection suggests acute flare-ups may be
205 experienced by a substantial number of patients. These episodes often last a week or
206 longer, are disruptive, prompt changes in self-management, and may be triggered by high-
207 loading physical activities.

208 Author Contributions

209

210 All authors were involved in conception and design of the study, analysis and interpretation
211 of data, drafting the article, critical revision of the article for important intellectual content,
212 final approval of the article. GP takes responsibility for the integrity of the work as a whole
213 from inception to finished article.

214

215 Role of the funding source

216

217 The paper presents research funded by Arthritis Research UK [Centre of Excellence award:
218 18139]. ELP received funding from a National Institute for Health Research (NIHR) In-
219 Practice Fellowship, NIHR Academic Clinical Fellowship and SPCR GP Progression Fellowship.

220

221 The views expressed are those of the author(s) and not necessarily those of the NHS, the
222 NIHR or the Department of Health.

223

224 Competing interest

225

226 GP received consultancy fees from InFirst plc and Good Relations plc.

227

228

229 **References**

- 230 1. Nicholls E, Thomas E, van der Windt DA, Croft PR, Peat G. Pain trajectory groups in
231 persons with, or at high risk of, knee osteoarthritis: findings from the Knee Clinical
232 Assessment Study and the Osteoarthritis Initiative. *Osteoarthritis and Cartilage*
233 2014;22:2041-50. DOI: <http://dx.doi.org/10.1016/j.joca.2014.09.026>.
- 234 2. Murphy SL, Lyden AK, Kratz AL, Fritz H, Williams DA, Clauw DJ, *et al*. Characterizing pain
235 flares from the perspective of individuals with symptomatic knee osteoarthritis. *Arthritis*
236 *Care and Research* 2015;67:1103-11. DOI: 10.1002/acr.22545.
- 237 3. Hawker GA, Stewart L, French MR, Cibere J, Jordan JM, March L, *et al*. Understanding the
238 pain experience in hip and knee osteoarthritis – an OARSI/OMERACT initiative.
239 *Osteoarthritis and Cartilage* 2008;16:415-22. DOI:
240 <http://dx.doi.org/10.1016/j.joca.2007.12.017>.
- 241 4. Ricci JA, Stewart WF, Chee E, Leotta C, Foley K, Hochberg MC. Pain Exacerbation as a
242 Major Source of Lost Productive Time in US Workers With Arthritis. *Arthritis and*
243 *Rheumatism* 2005;53:673-81. DOI: 10.1002/art.21453.
- 244 5. Marty M, Hilliquin P, Rozenberg S, Valat JP, Vignon E, Coste P, *et al*. Validation of the
245 KOFUS (Knee Osteoarthritis Flare-Ups Score). *Joint Bone Spine* 2009;76:268-72. DOI:
246 <http://dx.doi.org/10.1016/j.jbspin.2008.07.018>.
- 247 6. Parry EL, Thomas MJ, Peat G. Defining acute flares in knee osteoarthritis: a systematic
248 review. *BMJ Open* 2018;8:e019804. DOI: :10.1136/ bmjopen-2017-019804.

249

250 7. Zobel I, Erfani T, Bennell KL, Makovey J, Metcalf B, Chen JS, *et al.* Relationship of Buckling
251 and Knee Injury to Pain Exacerbation in Knee Osteoarthritis: A Web-Based Case-Crossover
252 Study. *Interact. J. Med. Res.* 2016;5:e17. DOI: 10.2196/ijmr.5452.

253 8. Trappenburg JCA, Monnikhof EM, Bourbeau J, Troosters T, Schrijvers AJP, Verheij TJM, *et*
254 *al.* Effect of an action plan with ongoing support by a case manager on exacerbation-related
255 outcome in patients with COPD: a multicentre randomised controlled trial. *Thorax*
256 2011;66:977-84. DOI: 10.1136/thoraxjnl-2011-200071.

257 9. Turk DC, Dworkin RH, Burke LB, Gershon R, Rothman M, Scott J, *et al.* Developing patient-
258 reported outcome measures for pain clinical trials: IMMPACT recommendations. *Pain*
259 2006;125:208-215. DOI: 10.1016/j.pain.2006.09.028.

260 10. Dworkin RH, Turk DC, Revicki DA, Harding G, Coyne KS, Peirce-Sandner S, *et al.*
261 Development and initial validation of an expanded and revised version of the Short-form
262 McGill Pain Questionnaire (SF-MPQ-2). *Pain* 2009;144:35-42. DOI:
263 10.1016/j.pain.2009.02.007.

264 11. Cooper C, McAlindon T, Coggon D, Egger P, Dieppe P. Occupational activity and
265 osteoarthritis of the knee. *Ann.Rheum.Dis.* 1994;53:90-3.

266 12. Harris RE, Williams DA, McLean SA, Sen A, Hufford M, Gendreau RM, *et al.*
267 Characterization and consequences of pain variability in individuals with fibromyalgia.
268 *Arthritis and Rheumatism* 2005;52:3670-4. DOI: 10.1002/art.21407.

- 269 13. Burge S and Wedzicha JA. COPD exacerbations: definitions and classifications.
270 Eur.Respir.J. 2003;21:46s-53s.
- 271 14. Maclure M. The Case-Crossover Design: A Method for Studying Transient Effects on the
272 Risk of Acute Events. Am.J.Epidemiol. 1991;133:144-53.
- 273 15. Schneider S, Junghaenel DU, Keefe FJ, Schwartz JE, Stone AA, Broderick JE. Individual
274 differences in the day-to-day variability of pain, fatigue, and well-being in patients with
275 rheumatic disease: Associations with psychological variables. Pain 2012;153:813-22. DOI:
276 10.1016/j.pain.2012.01.001.

277

278

279 **FIGURE LEGENDS**

280 **Figure 1.** Time course of an 'average' flare from 7 days prior to 30 days after the onset of a
281 flare (day 0). Points are group-mean pain intensity for all participants' first flares combined
282

283 **Table 1:** Table 1: Severity and occurrence of symptoms and impact experienced during flare
284 days versus at-risk days among participants experiencing one or more flare (n=30).

285
286 **Supplementary data 1:** Example diary page
287

288 **Supplementary data 2:** Illustrative examples of variability in daily knee pain intensity (0-
289 10NRS) and flares for two participants
290

291 **Supplementary data 3:** Crude ORs for physical activity exposures using discordant pairs
292

293 **Table 1: Severity and occurrence of symptoms and impact experienced during flare-up**
 294 **days versus at-risk days among participants experiencing one or more flare-ups (n=30).**

	Flare-up days [†] (n=299)	Non-flare-up days [‡] (n=1958)	Relative frequency/severity on flare-up days vs non-flare-up days*
Average knee pain intensity (0-10NRS): mean (SD)	5.4 (1.9)	3.1 (2.0)	2.5 (2.3, 2.6)
Pain descriptors			
Dull	52 (17)	673(35)	0.4 (0.2, 0.7)
Aching	218 (73)	1122 (59)	6.9 (4.1, 11.6)
Throbbing	95 (32)	301 (16)	18.1 (9.8, 33.3)
Sharp	146 (49)	206 (11)	11.2 (6.8, 18.6)
Stabbing	108 (36)	269 (14)	11.8 (7.2, 19.5)
Burning	73 (24)	171 (9)	6.7 (4.0, 11.1)
Numbness	72 (24)	15 (1)	6.7 (1.9, 23.1)
Pins and needles	1 (<1)	1 (<1)	-
Other	9 (3)	45 (2)	1.3 (0.6, 3.1)
Knee swelling	149 (50)	668 (35)	14.5 (8.3, 25.4)
Limping	191 (64)	804 (42)	12.4 (7.4, 20.8)
Knee stiffness lasting >20 mins	178 (60)	505 (26)	10.9 (7.0, 17.1)
Woken at night by knee pain	103 (35)	189 (10)	7.0 (4.3, 11.2)
Taking more medication than usual	94 (34)	181 (12)	23.9 (13.8, 41.4)
Pain stopped usual activities	44 (15)	76 (4)	26.5 (13.7, 51.5)

Figures are n (%) unless otherwise stated

[†] Days during a flare-up (i.e. from start of flare-up to first day when pain returned to 'normal' levels for 5 consecutive days; [‡] excludes flare-up days as well as the 5 consecutive days after last flare-up day

NRS Numerical rating scale; SD Standard deviation

*From mixed-effect model (logistic for binary and linear for continuous outcome). Results are expressed as odds ratios (95% CI) except average knee pain intensity which is expressed as a regression coefficient (i.e. mean difference) and 95% CI

295

296

297

Table 1: Severity and occurrence of symptoms and impact experienced during flare-up days versus at-risk days among participants experiencing one or more flare-ups (n=30).

	Flare-up days [†] (n=299)	Non-flare-up days [‡] (n=1958)	Relative frequency/severity on flare-up days vs non-flare-up days*
Average knee pain intensity (0-10NRS): mean (SD)	5.4 (1.9)	3.1 (2.0)	2.5 (2.3, 2.6)
Pain descriptors			
Dull	52 (17)	673(35)	0.4 (0.2, 0.7)
Aching	218 (73)	1122 (59)	6.9 (4.1, 11.6)
Throbbing	95 (32)	301 (16)	18.1 (9.8, 33.3)
Sharp	146 (49)	206 (11)	11.2 (6.8, 18.6)
Stabbing	108 (36)	269 (14)	11.8 (7.2, 19.5)
Burning	73 (24)	171 (9)	6.7 (4.0, 11.1)
Numbness	72 (24)	15 (1)	6.7 (1.9, 23.1)
Pins and needles	1 (<1)	1 (<1)	-
Other	9 (3)	45 (2)	1.3 (0.6, 3.1)
Knee swelling	149 (50)	668 (35)	14.5 (8.3, 25.4)
Limping	191 (64)	804 (42)	12.4 (7.4, 20.8)
Knee stiffness lasting >20 mins	178 (60)	505 (26)	10.9 (7.0, 17.1)
Woken at night by knee pain	103 (35)	189 (10)	7.0 (4.3, 11.2)
Taking more medication than usual	94 (34)	181 (12)	23.9 (13.8, 41.4)
Pain stopped usual activities	44 (15)	76 (4)	26.5 (13.7, 51.5)

Figures are n (%) unless otherwise stated

[†] Days during a flare-up (i.e. from start of flare-up to first day when pain returned to 'normal' levels for 5 consecutive days; [‡] excludes flare-up days as well as the 5 consecutive days after last flare-up day

NRS Numerical rating scale; SD Standard deviation

*From mixed-effect model (logistic for binary and linear for continuous outcome). Results are expressed as odds ratios (95% CI) except average knee pain intensity which is expressed as a regression coefficient (i.e. mean difference) and 95% CI

Figure 1: Time course of an 'average' flare-up from 7 days prior to 30 days after the onset of a flare (day 0). Points are group-mean pain intensity for all participants' first flare-ups combined

